Skip to content

Released Nov 3, 2022, after the close

10-Q filed Nov 3, 2022, 34 days after period end · 0000950170-22-021840

Q3 2022 · 10-Q
Revenue$14.98M+5.3% vs Q3 2021−19.2% vs Q2 2022
Net Income-$83.56MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.86N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$86,391,000N/M
Operating Cash Flowderived-$55,047,000N/M
Free Cash Flowderived-$63,723,000N/M
Margins · derived
Operating margin-576.7%−192.7 pt vs Q3 2021
Net margin-557.8%−253.3 pt vs Q3 2021

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020Q3 2019
Revenue$14.98M$14.23M$7.56M$2.43M
Net Income-$83.56M-$43.31M-$58.68M-$26.61M
EPS Diluted-$0.86-$0.45-$0.68-$0.40

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR